Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

Item

http://www.wikidata.org/entity/Q33389572

Q33389572

about

PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1 The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation Targeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase EmPlk1 Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma.Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers.Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.Aberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival.Remote loading of preencapsulated drugs into stealth liposomes.Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Current assessment of polo-like kinases as anti-tumor drug targets.Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.Small molecules in combination with conventional chemotherapeutic drugs: Light at the end of the tunnel?Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization.Identification of Polo-like kinases as potential novel drug targets for influenza A virus.Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck.

P2860

Q26777811-E69B52AE-40CB-47B1-BE8B-A17D392867C3 Q26991736-A6082C91-DC43-4115-BEB7-04F542A1C913 Q27024775-45B7B367-D0B1-46A1-B8D2-AD23D43E6C2C Q27304385-9BDC942B-3FE1-4849-B377-C63FC921CD6D Q27319063-5AD3D10C-D757-44BF-AA25-0E5CCA268DDB Q28478937-41F1AE0F-91D0-4DB4-B24F-5CD42BA113D9 Q28539389-9906A162-A5C5-4596-9357-EC62BA38E8A0 Q33713695-C2041DEE-35C5-458A-8D59-921C25BE427A Q33731350-403C8372-AF78-4F27-9B49-4C4761B6F666 Q33938849-06C7DE0D-654C-4122-9CAC-D140165DA831 Q34042731-BBB718BA-CD1A-4703-8ACF-AE9C8814D1FB Q34152071-4D521AF6-E2D5-4451-8C5E-5DEC1A7691D8 Q35130666-C25A8D2B-8496-4C8B-874C-4C089936B830 Q35371690-D572BDA1-74A0-4C8E-A04B-E38A2AC84E02 Q35843942-43C7A53D-67FC-4820-A367-32FCFB750BA3 Q36062154-5F60BF2A-3A79-4A84-A5A0-616D30FA2994 Q36629870-30ED7770-E456-440D-995D-54991E380435 Q36759439-9690F4D4-34F9-421F-BB72-76978F0D38DE Q37377959-C48CE122-E9A1-4218-A68E-73FE62A514C7 Q37552296-D602A3D9-92D0-4DC9-8B86-9C39E2E692E6 Q37587698-77FE97C0-77B6-4157-B862-6AC25D5631DE Q37909373-3EC416A6-53ED-4C20-BD78-4602E76B03E3 Q37994256-3F981A42-499A-4C8F-A6A9-4C293D91E5B8 Q38099046-5D815B4B-AC9E-469C-A73B-A940AF068D5E Q38211244-52AF99E6-62E3-42B1-85A8-7E41A19EFF8D Q38292744-B97E7DA2-9B2A-49FE-A4CD-B4F060522A43 Q38362686-C856DDAD-CCDA-464F-8115-709DB4CDF08A Q38366458-DB15F93C-957C-409C-BFF5-3698D3917589 Q38637013-6BEBD1B9-D8B2-433A-97C6-9C769AEEA124 Q38719309-6250DCF9-57C2-40A2-95CE-AF331F90053A Q38884906-8C77EDD6-F184-4C87-A7A2-28AB21804DEE Q39120232-9A2AB46E-C903-47E8-9D85-1B1928D620A7 Q39136346-5525E1F0-33CE-4C8A-97EC-D202A9BF8F21 Q39242775-4DF4C764-01B5-4BA6-8456-CC73BE2F3C16 Q39633115-45CCBA59-2469-49AE-9651-7F761F7BC613 Q39767815-88B01B4B-5788-41B7-AB91-5C862029FEDF Q40078929-340D1D67-AB58-4C48-8CD1-6C4EC3D6EEFA Q41582116-A286BBF7-1C47-4A40-BDEB-198235C301E3 Q41866750-1072C25C-E8CE-4A1A-8058-58B2C134406B Q42036348-F6965E7E-E887-4E25-B4C2-DEAC7CFB5D71

P2860

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

Item

http://www.wikidata.org/entity/Q33389572

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu